Immune regulation by CD52-expressing CD4 T cells

[1]  L. Harrison,et al.  T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10 , 2013, Nature Immunology.

[2]  Clelia Di Serio,et al.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells , 2013, Nature Medicine.

[3]  S. Sakaguchi,et al.  Development and maintenance of regulatory T cells. , 2013, Immunity.

[4]  P. Tipping,et al.  Cytokine Therapy With Interleukin-2/Anti–Interleukin-2 Monoclonal Antibody Complexes Expands CD4+CD25+Foxp3+ Regulatory T Cells and Attenuates Development and Progression of Atherosclerosis , 2012, Circulation.

[5]  S. Pillai,et al.  Siglecs and immune regulation. , 2012, Annual review of immunology.

[6]  Joanne L. Jones,et al.  Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis , 2012, Expert review of neurotherapeutics.

[7]  J. Ferdinand,et al.  Expression of TNFRSF25 on conventional T cells and Tregs. , 2011, The Journal of clinical investigation.

[8]  T. Malek,et al.  Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. , 2010, The Journal of clinical investigation.

[9]  S. Jalkanen,et al.  Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. , 2009, Blood.

[10]  J. Gribben,et al.  Rediscovering alemtuzumab: current and emerging therapeutic roles , 2009, British journal of haematology.

[11]  M. Ikawa,et al.  Cd52, known as a major maturation‐associated sperm membrane antigen secreted from the epididymis, is not required for fertilization in the mouse , 2008, Genes to cells : devoted to molecular & cellular mechanisms.

[12]  Tomoko Watanabe,et al.  CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. , 2006, Clinical immunology.

[13]  K. Busam,et al.  Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. , 2003, Blood.

[14]  S. Kano,et al.  A Novel Costimulation Pathway Via the 4C8 Antigen for the Induction of CD4+ Regulatory T Cells1 , 2002, The Journal of Immunology.

[15]  J. Lafaille,et al.  Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell Function , 2002, The Journal of experimental medicine.

[16]  K. Cheng,et al.  A new siglec family member, siglec-10, is expressed in cells of the immune system and has signaling properties similar to CD33. , 2001, European journal of biochemistry.

[17]  Nan Li,et al.  Cloning and Characterization of Siglec-10, a Novel Sialic Acid Binding Member of the Ig Superfamily, from Human Dendritic Cells* , 2001, The Journal of Biological Chemistry.

[18]  S. Naaby-Hansen,et al.  N‐linked glycan of a sperm CD52 glycoform associated with human infertility , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  S. Kano,et al.  Characterization of the 4C8 Antigen Involved in Transendothelial Migration of CD26hi T Cells after Tight Adhesion to Human Umbilical Vein Endothelial Cell Monolayers , 1999, The Journal of experimental medicine.

[20]  K. Spiekermann,et al.  Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. , 1996, Blood.

[21]  G. Hale.  Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. , 1995, Immunotechnology : an international journal of immunological engineering.

[22]  B. Beutler,et al.  A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity , 1991, The Journal of experimental medicine.

[23]  G. Hale,et al.  Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. , 1983, Blood.

[24]  H. Wiendl,et al.  Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. , 2013, Nature reviews. Neurology.

[25]  N. Robertson.  Alemtuzumab for multiple sclerosis: a new age of immunotherapy , 2012, Journal of Neurology.

[26]  A. Minagar.  Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort , 2012 .

[27]  A. Varki,et al.  Siglecs--the major subfamily of I-type lectins. , 2006, Glycobiology.

[28]  M. Feldmann,et al.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.

[29]  D. Galas,et al.  Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse , 2001, Nature Genetics.

[30]  C. Kirchhoff.  CD52 is the 'major maturation-associated' sperm membrane antigen. , 1996, Molecular human reproduction.